乳腺癌耐药蛋白在非霍奇金淋巴瘤中的表达及意义  

The expression of breast cancer resistance protein in patients with non-Hodgkin lymphoma

作　　者：钱素英[1] 毛联刚[1] 吴宁宁[1] 方治[1] 陈亚敏[1] 童向民[2] 李克强[1] 夏兆雄[1] 

机构地区：[1]宁波市第二医院血液科,浙江宁波315010 [2]浙江大学医学院附属第一医院血液科

出　　处：《临床血液学杂志》2010年第1期29-31,共3页Journal of Clinical Hematology

基　　金：宁波市卫生局课题(No:2002036)

摘　　要：目的:探讨非霍奇金淋巴瘤(NHL)患者乳腺癌耐药蛋白(BCRP)的表达及临床意义。方法:采用RT-PCR法检测66例NHL患者新鲜淋巴组织标本BCRP及多药耐药基因(MDR1)的表达,并对所有患者进行随访。结果:66例NHL患者BCRP阳性率45.5%,MDR1阳性率59.1%;不同类型、不同临床分期BCRP阳性率不同;BCRP基因有无表达其缓解率、复发率、5年生存率不同;BCRP+MDR1+、BCRP+MDR1-、BCRP-MDR1+、BCRP-MDR1-4组化疗疗效不同(P<0.05)。结论:本组NHL患者BCRP及MDR1表达率高,是化疗敏感性差的重要原因。Objective： To investigate the expression of breast cancer resistance protein （BCRP） gene and drug resistance in patients with non-Hodgkin lymphoma. Method： The expression of BCRP and MDR1 gene in 66 NHL cases were examed by reverse transcriptase polymerase chain reaction （RT PCR）. All patients were followed-up. Result：The positive ratio of BCRP gene was 45.5% and MDR1 gene was 59.1% in 66 NHL respectively. There was different positive ratio of BCRP gene in different pathologic types and clinical stages. The remission rate, recurrence rate and 5 years survival rate were all related with the expression of BCRP; The response of treatment were different among the group of BCRP^＋MDR1^＋ , BCRP^＋ MDR1 , BCRP MDR1^＋ , and BCRP^- MDR1^- （P 〈0. 05）. Conclusion：The poor response of therapy has close relation with the high expression of BCRP and MDR1.

关 键 词：非霍奇金淋巴瘤 乳腺癌耐药蛋白 多药耐药基因 

分 类 号：R733.4[医药卫生—肿瘤]